Listed

Balchem Corp: Form 10-Q for the period ended Sep 30, 2019

Filed with the SEC on Nov 5, 2019 and accepted by EDGAR at Nov 5, 2019, 14:38 ET.

Share

Management's discussion and analysis

As filed, 21,886 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

This report contains forward-looking statements, within the meaning of Section 21E of the Exchange Act, which reflect our expectation or belief concerning future events that involve risks and uncertainties. Actions and performance could differ materially from what is contemplated by the forward-looking statements contained in this report. Factors that might cause differences from the forward-looking statements include those referred to or identified in Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2018 and other factors that may be identified elsewhere in this report. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements.

Overview

We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Our four reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition & Health, Animal Nutrition & Health, Specialty Products, and Industrial Products, as more fully described in Note 11 of the condensed consolidated financial statements.

We sell products for all four segments through our own sales force, independent distributors, and sales agents.

The following tables summarize consolidated net sales by segment and business segment earnings from operations for the three and nine months ended September 30, 2019 and 2018:

Business Segment Net Sales:

Three Months Ended September 30, 2019 2018 Nine Months Ended September 30, 2019 2018
Human Nutrition & Health $86,142 $85,890 $257,163 $253,966
Animal Nutrition & Health 42,286 40,410 129,127 128,587
Specialty Products 24,888 17,629 68,219 58,233
Industrial Products 5,279 11,114 22,669 39,354
Total $158,595 $155,043 $477,178 $480,140

27

Business Segment Earnings From Operations:

Three Months Ended September 30, 2019 2018 Nine Months Ended September 30, 2019 2018
Human Nutrition & Health $13,193 $13,107 $39,234 $35,724
Animal Nutrition & Health 6,122 5,100 16,423 19,607
Specialty Products 6,699 5,767 22,275 19,476
Industrial Products 842 1,751 3,390 6,843
Transaction and integration costs, ERP implementation costs, and unallocated legal fees (688) (202) (2,253) (1,784)
Unallocated amortization expense (138) — (157) —
Total $26,030 $25,523 $78,912 $79,866

Acquisition of Chemogas Holding NV

On May 27, 2019, we acquired 100 percent of the outstanding common shares of Chemogas, a privately held specialty gases company headquartered in Grimbergen, Belgium. We made payments of approximately €99,503 (translated to $111,324) on the acquisition date, amounting to approximately €88,579 (translated to $99,102) to the former shareholders and approximately €10,924 (translated to $12,222) to Chemogas' lender to pay off all Chemogas bank debt. Considering the cash acquired of €3,943 (translated to $4,412), net payments made to the former shareholders were €84,636 (translated to $94,690). The acquisition was primarily financed through our Credit Agreement. Chemogas has been a leader in the packaging and distribution of a wide variety of specialty gases, most notably ethylene oxide, primarily in the European and Asian markets, for medical device sterilization. Through its operational and logistical excellence, Chemogas supports its customers' needs across more than 70 countries. With the acquisition, we significantly expand our geographic presence in the packaged ethylene oxide market, enabling us to offer worldwide service and support to its medical device sterilization customers within the Specialty Products segment. The Chemogas sites in Europe and Asia will form a global network of facilities when combined with Balchem's sites in the United States.

RESULTS OF OPERATIONS

(All amounts in thousands, except share and per share data)

Three months ended September 30, 2019 compared to three months ended September 30, 2018.

Net Sales

Net sales for the three months ended September 30, 2019 were $158,595, as compared with $155,043 for the three months ended September 30, 2018, an increase of $3,552 or 2.3%. Net sales for the Human Nutrition & Health segment were $86,142 for the three months ended September 30, 2019, compared with $85,890 for the three months ended September 30, 2018, an increase of $252 or 0.3%. The increase was primarily driven by higher sales within our Human Nutrition & Pharma business, partially offset by lower Cereal Systems volumes. Net sales for the Animal Nutrition & Health segment were $42,286 for the three months ended September 30, 2019, as compared with $40,410 for the three months ended September 30, 2018, an increase of $1,876 or 4.6%. The increase was primarily the result of higher sales of ruminant animal feed market products. Net sales for the Specialty Products segment were $24,888 for the three months ended September 30, 2019, as compared with $17,629 for the three months ended September 30, 2018, an increase of $7,259 or 41.2%. The increase was primarily due to higher ethylene oxide sales into the medical device sterilization market due to both the contribution of Chemogas and higher legacy product sales, partially offset by lower volumes in the plant nutrition business. Net sales for the Industrial Products segment were $5,279 for the three months ended September 30, 2019 as compared to $11,114 for the three months ended September 30, 2018, a decrease of $5,835 or 52.5%. The decrease is principally due to lower sales volumes of various choline and choline derivatives used in shale fracking applications.

Gross Margin

For the three months ended September 30, 2019, gross margin increased to $54,008 compared to $48,002 for the three months ended September 30, 2018, an increase of $6,006 or 12.5%. Gross margin as a percentage of sales for the three months ended September 30, 2019 increased to 34.1% from 31.0% in the prior year comparative period. Gross margin percentage for the Human Nutrition & Health segment increased 2.5% for the three months ended September 30, 2019 as compared to the three months ended September 30, 2018 primarily due to mix, certain lower raw material costs and manufacturing efficiencies. Gross margin percentage increased for Animal Nutrition & Health by 2.8% primarily due to mix, certain lower raw material costs, and manufacturing efficiencies, partially offset by lower margins in the European monogastric business. Gross margin percentage for the Specialty Products decreased 4.9% compared to the three month period ended September 30, 2018 primarily due to mix. Industrial Products gross margin percentage increased 7.8% from the prior year comparative period, primarily due to certain lower raw material costs and mix.

Operating Expenses

Operating expenses for the three months ended September 30, 2019 were $27,978 or 17.6% of net sales as compared to $22,479 or 14.5% of net sales for the three months ended September 30, 2018. The increase was primarily due to the timing of an insurance recovery of $2,575 received in 2018 and incremental operating expenses related to the Chemogas acquisition of $2,072.

Earnings from Operations

Principally as a result of the above-noted details, earnings from operations for the three months ended September 30, 2019 were $26,030 as compared to $25,523 for the three months ended September 30, 2018, an increase of $507 or 2.0%. Earnings from operations as a percentage of sales were 16.4% and 16.5% for the three months ended September 30, 2019 and 2018, respectively. Earnings from the Human Nutrition & Health segment were $13,193, an increase of $86 or 0.7%, primarily due to the aforementioned higher sales and mix, partially offset by higher operating expenses resulting from the prior year benefiting from the timing of an insurance recovery. Animal Nutrition & Health segment earnings from operations were $6,122, a increase of $1,022 or 20.0%, primarily the result of the aforementioned higher sales of products targeted for ruminant animal feed markets and certain lower raw material costs, partially offset by lower margins in the European monogastric business as a result of increased competitive activity. Earnings from operations from the Specialty Products segment were $6,699, an increase of $932 or 16.2%, primarily due to the aforementioned higher sales, partially offset by mix and higher operating expenses due to the acquisition of Chemogas. Earnings from operations from the Industrial Products segment of $842 for the three months ended September 30, 2019 decreased $909 compared to the three months ended September 30, 2018, primarily due to the aforementioned lower sales volumes.

Other Expenses (Income)

Interest expense for the three months ended September 30, 2019 and 2018 was $1,672 and $1,797, respectively, which is primarily related to outstanding borrowings under the Credit Agreement. Other income was $78 for the three months ended September 30, 2019 and other expense was $197 for the three months ended September 30, 2018.

Income Tax Expense

Our effective tax rate for the three months ended September 30, 2019 and 2018, was 15.4% and 18.3%, respectively. The decrease was attributable to discrete items.

Net Earnings

Principally as a result of the above-noted details, net earnings for the three months ended September 30, 2019 were $20,676 as compared with $19,214 for the three months ended September 30, 2018, an increase of $1,462 or 7.6%.

Nine months ended September 30, 2019 compared to nine months ended September 30, 2018.

Net Sales

Net sales for the nine months ended September 30, 2019 were $477,178, as compared with $480,140 for the nine months ended September 30, 2018, a decrease of $2,962 or 0.6%. Net sales for the Human Nutrition & Health segment were $257,163 for the nine months ended September 30, 2019, compared with $253,966 for the nine months ended September 30, 2018, an increase of $3,197 or 1.3%. Sales within our Ingredient Solutions business into food and beverage markets were up $2,353 or 1.3% compared to the nine months ended September 30, 2018. Net sales for the Animal Nutrition & Health segment were $129,127 for the nine months ended September 30, 2019, as compared with $128,587 for the nine months ended September 30, 2018, an increase of $540 or 0.4%. The increase was primarily the result of higher sales of ruminant animal feed market products. Net sales for the Specialty Products segment were $68,219 for the nine months ended September 30, 2019, as compared with $58,233 for the nine months ended September 30, 2018, an increase of $9,986 or 17.1%. The increase was primarily due to higher ethylene oxide sales into the medical device sterilization market due to both the contribution of Chemogas and higher legacy product sales, partially offset by lower volumes in the plant nutrition business. Net sales for the Industrial Products segment were $22,669 for the nine months ended September 30, 2019 as compared to $39,354 for the nine months ended September 30, 2018, a decrease of $16,685 or 42.4%. The decrease is principally due to lower sales volumes of various choline and choline derivatives used in shale fracking applications.

Gross Margin

For the nine months ended September 30, 2019, gross margin increased to $157,021 compared to $152,927 for the nine months ended September 30, 2018, an increase of $4,094 or 2.7%. Gross margin as a percentage of sales was 32.9% and 31.9% for the nine months ended September 30, 2019 and September 30, 2018. Gross margin percentage for the Human Nutrition & Health segment increased by 0.8% for the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018, primarily due to mix. Gross margin percentage decreased for Animal Nutrition & Health by 0.7% primarily due to lower global feed grade choline volumes and margins in the European monogastric business as a result of increased competitive activity. Gross margin percentage for the Specialty Products decreased 0.6% compared to the nine month period ended September 30, 2018 primarily due to the impact from Chemogas. Industrial Products gross margin percentage increased by 1.9% compared with the prior year comparable period primarily due to certain lower raw material costs and mix.

Operating Expenses

Operating expenses for the nine months ended September 30, 2019 were $78,109 or 16.4% of net sales as compared to $73,061 or 15.2% of net sales for the nine months ended September 30, 2018. The increase was primarily due to incremental operating expenses related to the Chemogas acquisition of $2,885, a decrease in insurance proceeds associated with the Clearfield fire of $1,438, and increased bad debt expense of $908.

Earnings from Operations

Principally as a result of the above-noted details, earnings from operations for the nine months ended September 30, 2019 were $78,912 as compared to $79,866 for the nine months ended September 30, 2018, a decrease of $954 or 1.2%. Earnings from operations as a percentage of sales were 16.5% and 16.6% for the nine months ended September 30, 2019 and 2018, respectively. Earnings from the Human Nutrition & Health segment were $39,234 an increase of $3,510 or 9.8%, primarily due to the aforementioned higher sales and mix. Animal Nutrition & Health segment earnings from operations were $16,423, a decrease of $3,184 or 16.2%, primarily the result of lower global feed grade choline volumes and margins in the European monogastric business as a result of increased competitive activity. Earnings from operations from the Specialty Products segment were $22,275, an increase of $2,799 or 14.4%, primarily due to higher sales and the contribution from Chemogas. Earnings from operations from the Industrial Products segment of $3,390 for the nine months ended September 30, 2019 decreased $3,453 compared to the nine months ended September 30, 2018, primarily due to the aforementioned lower sales volumes.

Other Expenses (Income)

Interest expense for the nine months ended September 30, 2019 and 2018 was $4,749 and $5,936, respectively, which is primarily related to outstanding borrowings under the Credit Agreement. Other expense was $53 and $163 for the nine months ended September 30, 2019 and 2018, respectively.

Income Tax Expense

Our effective tax rate was 20.0% and 21.1% for the nine months ended September 30, 2019 and 2018, respectively.

Net Earnings

Principally as a result of the above-noted details, net earnings for the nine months ended September 30, 2019 were $59,288 as compared with $58,239 for the nine months ended September 30, 2018, an increase of $1,049 or 1.8%.

FINANCIAL CONDITION

LIQUIDITY AND CAPITAL RESOURCES

(All amounts in thousands, except share and per share data)

During the nine months ended September 30, 2019, there were no material changes outside the ordinary course of business in the specified contractual obligations set forth in our Annual Report on Form 10-K for the year ended December 31, 2018. We expect our operations to continue generating sufficient cash flow to fund working capital requirements and necessary capital investments. We are actively pursuing additional acquisition candidates. We could seek additional bank loans or access to financial markets to fund such acquisitions, our operations, working capital, necessary capital investments or other cash requirements should we deem it necessary to do so.

Cash

Cash and cash equivalents increased to $59,404 at September 30, 2019 from $54,268 at December 31, 2018. At September 30, 2019, the Company had $29,768 of cash and cash equivalents held by foreign subsidiaries. It is our intention to permanently reinvest these funds in foreign operations by continuing to make additional plant related investments, and potentially invest in partnerships or acquisitions; therefore, we do not currently expect to repatriate these funds in order to fund U.S. operations or obligations. However, if these funds are needed for U.S. operations, we could be required to pay additional withholding taxes to repatriate these funds. Working capital was $167,926 at September 30, 2019 as compared to $144,258 at December 31, 2018, an increase of $23,668. Working capital reflects the payment of the 2018 declared dividend in 2019 of $15,135 and proceeds from the sale of business and assets.

Operating Activities

Cash flows from operating activities provided $91,494 for the nine months ended September 30, 2019 as compared to $79,185 for the nine months ended September 30, 2018. The increase in cash flows from operating activities was primarily due to working capital changes and an increase in earnings.

Investing Activities

As previously noted, on May 27, 2019, we acquired 100 percent of the outstanding common shares of Chemogas Holding, NV and its Subsidiaries ("Chemogas" or the "Acquisition"), a privately held specialty gases company headquartered in Grimbergen, Belgium. Cash paid for the acquisition, net of cash acquired, amounted to $94,690.

As noted above, on September 6, 2019, we sold an insignificant portion of the business which is included in "proceeds from sale of business and assets" in the condensed consolidated statements of cash flows.

We continue to invest in corporate projects, improvements across all production facilities, and intangible assets. Total investments in property, plant and equipment and intangible assets were $21,669 and $13,691 for the nine months ended September 30, 2019 and 2018, respectively.

Financing Activities

As previously noted, the acquisition of Chemogas was primarily funded through our credit agreement. We borrowed $123,569 against the revolving loan and also made payments of $12,222 on the acquired debt. Total debt payments on the revolving loan amounted to $61,000 during 2019 and we have $281,431 available under the credit agreement as of September 30, 2019.

We have an approved stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 2,431,767 shares have been purchased, and we had 232,499 shares remaining in treasury at September 30, 2019. We intend to acquire shares from time to time at prevailing market prices if and to the extent we deem it is advisable to do so based on our assessment of corporate cash flow, market conditions and other factors. The Company also repurchases shares from employees in connection with settlement of transactions under the Company's equity incentive plans.

Proceeds from stock options exercised were $3,734 and $8,133 for the nine months ended September 30, 2019 and 2018, respectively. Dividend payments were $15,135 and $13,428 for the nine months ended September 30, 2019 and 2018, respectively.

Other Matters Impacting Liquidity

We currently provide postretirement benefits in the form of two retirement medical plans, as discussed in Note 15 – Employee Benefit Plans. The liability recorded in other long-term liabilities on the condensed consolidated balance sheets as of September 30, 2019 and December 31, 2018 was $1,250 and $1,174, respectively, and the plans are not funded. Historical cash payments made under these plans have typically been less than $100 per year. We do not anticipate any changes to the payments made in the current year for the plans.

On June 1, 2018, we established an unfunded, nonqualified deferred compensation plan maintained for the benefit of a select group of management or highly compensated employees. Assets of the plan are held in a rabbi trust, which are subject to additional risk of loss in the event of bankruptcy or insolvency of the Company. The deferred compensation liability as of September 30, 2019 and December 31, 2018 was $1,803 and $265, respectively, and is included in other long-term obligations on our balance sheet.

On May 27, 2019, we acquired Chemogas, which had two defined benefit pension plans (DB plans), one of which was closed on December 31, 2018 and replaced by four individual defined contribution plans. The active pension plan is funded by means of employee and Company contributions and provide for the payment of a lump sum at retirement or payments in case of death of the covered employees. The DB plan is considered a post-employment benefit. The amount recorded for these obligations on our balance sheets as of September 30, 2019 was $580 and is included in other long-term obligations.

Critical Accounting Policies

In the second quarter of 2019, we entered into financial arrangements as part of our ongoing asset and liability management activities. We use derivative financial instruments to hedge fair values of underlying assets and liabilities or future cash flows which are exposed to interest rate or foreign currency fluctuations. We do not enter into derivative financial instruments for trading or speculative purposes. Refer to Note 20, "Derivative Instruments and Hedging Activities" for detailed information about our derivative financial instruments.

Other than what is noted above, there were no changes to the Company's Critical Accounting Policies, as described in its December 31, 2018 Annual Report on Form 10-K, during the nine months ended September 30, 2019.

Related Party Transactions

We were engaged in related party transactions with St. Gabriel CC Company, LLC during the three and nine months ended September 30, 2019. Refer to Note 18, "Related Party Transactions".

Market risk

As filed, 2,202 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our cash and cash equivalents are held primarily in certificates of deposit and money market investment funds. In the second quarter of 2019, we entered into an interest rate swap and cross-currency swap for hedging purposes. Refer to details noted below. Additionally, as of September 30, 2019, our borrowings were under a revolving loan bearing interest at a fluctuating rate as defined by the Credit Agreement plus an applicable rate. The applicable rate is based upon our consolidated net leverage ratio, as defined in the Credit Agreement. A 100 basis point increase or decrease in interest rates, applied to our borrowings at September 30, 2019, would result in an increase or decrease in annual interest expense and a corresponding reduction or increase in cash flow of approximately $2,186. We are exposed to commodity price risks, including prices of our primary raw materials. Our objective is to seek a reduction in the potential negative earnings impact of raw material pricing arising in our business activities. We manage these financial exposures, where possible, through pricing and operational means. Our practices may change as economic conditions change.

Interest Rate Risk

We have exposure to market risk for changes in interest rates, including the interest rate relating to our credit agreement dated June 27, 2018. In the second quarter of 2019, we began to manage our interest rate exposure through the use of derivative instruments. All of our derivative instruments are utilized for risk management purposes, and are not used for trading or speculative purposes. We have hedged a portion of our floating interest rate exposure using an interest rate swap (see Note 20 to our condensed consolidated financial statements). As of September 30, 2019, the notional amount of our outstanding interest rate swap was $108,569.

Foreign Currency Exchange Risk

We are also exposed to foreign currency exchange risk. Specifically, we are exposed to changes in exchange rates between the U.S. dollar and Euro. In the second quarter of 2019, we entered into a cross-currency swap, with a notional amount of $108,569, which we designated as a hedge of our net investment in Chemogas.

Controls and procedures

As filed, 966 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(a) Evaluation of Disclosure Controls and Procedures

Prior to filing this report, we completed an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Exchange Act as of September 30, 2019. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2019.

(b) Changes in Internal Controls

There have been no changes in the internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Act) during the fiscal quarter ended September 30, 2019, that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

Risk factors

As filed, 148 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes in the Risk Factors identified in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-07-01 to 2019-09-30$158.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2019-01-01 to 2019-09-30$477.2mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2019-07-01 to 2019-09-30$104.6mus-gaap:CostOfRevenue
Cost of revenue9 months2019-01-01 to 2019-09-30$320.2mus-gaap:CostOfRevenue
Gross profit3 months2019-07-01 to 2019-09-30$54.0mus-gaap:GrossProfit
Gross profit9 months2019-01-01 to 2019-09-30$157.0mus-gaap:GrossProfit
Research and development3 months2019-07-01 to 2019-09-30$2.7mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2019-01-01 to 2019-09-30$8.4mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2019-07-01 to 2019-09-30$26.0mus-gaap:OperatingIncomeLoss
Operating income9 months2019-01-01 to 2019-09-30$78.9mus-gaap:OperatingIncomeLoss
Income tax3 months2019-07-01 to 2019-09-30$3.8mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2019-01-01 to 2019-09-30$14.8mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-07-01 to 2019-09-30$20.7mus-gaap:NetIncomeLoss
Net income9 months2019-01-01 to 2019-09-30$59.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-07-01 to 2019-09-30$0.64us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2019-01-01 to 2019-09-30$1.82us-gaap:EarningsPerShareDiluted
Basic EPS3 months2019-07-01 to 2019-09-30$0.64us-gaap:EarningsPerShareBasic
Basic EPS9 months2019-01-01 to 2019-09-30$1.84us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2019-07-01 to 2019-09-3032,455,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2019-01-01 to 2019-09-3032,514,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2019-01-01 to 2019-09-30$91.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2019-01-01 to 2019-09-30$19.6mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2019-01-01 to 2019-09-30$15.1mus-gaap:PaymentsOfDividends
Share repurchases9 months2019-01-01 to 2019-09-30$21.3mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2019-09-30$59.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-09-30$239.9mus-gaap:AssetsCurrent
Total assetsAt period end2019-09-30$1.10bnus-gaap:Assets
Current liabilitiesAt period end2019-09-30$72.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-09-30$363.0mus-gaap:Liabilities
Shareholders' equityAt period end2019-09-30$733.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001628280-19-013298. Last ingested by Listed: Oct 24, 2026, 14:51 ET. Listed shows no prices and gives no investment advice.